Stevanato group reports revenue of €256.6 million for the first quarter of 2025

Piombino dese, italy--(business wire)--stevanato group s.p.a. (nyse: stvn), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. first quarter 2025 highlights (comparisons to prior-year period) revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. gross.
STVN Ratings Summary
STVN Quant Ranking